Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3 clinical trials
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for

monoclonal protein
hypercalcemia
plasmacytosis
bone marrow procedure
progressive disease
  • 27 views
  • 16 Jun, 2022
  • 4 locations
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

This phase Ib trial studies the side effects and best dose of navtemadlin when given together with the standard chemotherapy drugs cytarabine and idarubicin in patients with acute myeloid leukemia. Navtemadlin may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for cell growth. …

hemolysis
idarubicin
venetoclax
cancer
blast cells
  • 0 views
  • 14 Jun, 2022
  • 2 locations
Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

This phase Ib trial studies the side effects of navtemadlin and radiation therapy in treating patients with soft tissue sarcoma. Navtemadlin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink …

cancer chemotherapy
soft tissue sarcoma
ct scan
platelet count
cancer
  • 255 views
  • 16 Jun, 2022
  • 31 locations